Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary
November 4, 2024
Earnings Call Speaker Segments
Liz Krutoholow
executiveThanks, Briana. Good afternoon, everyone, and thanks for joining Tempus' call covering the third quarter of 2024; earlier today, Tempus posted its results for the quarter that closed on September 30, 2024. Here with me from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to note that management might make forward-looking statements on this call, and those statements carry risks and uncertainties that may lead actual results to differ materially. To review those risks, please see our 10-Q covering the quarter that ended September 30, 2024, which we filed on November 4, 2024, along with any upcoming reports we submit to the SEC. On this call, we'll also talk about non-GAAP financial measures, and those aren't prepared under generally accepted accounting principles. You can find definitions of those non-GAAP financial measures, plus reconciliations to the most directly comparable GAAP financial measures, in our third quarter earnings release, which has been furnished to the SEC and can be found on our website at investors.tempus.com. At this point, I'd like to hand the call over to Eric.
Eric Lefkofsky
executiveHello, everyone. Before we dive into Q&A, I wanted to take a moment to walk through a few key points from the quarter. Tempus had a strong Q3. Our revenue climbed 33%, reaching $180.9 million; unit growth in Genomics sped up from the prior quarter to 23.9%, a meaningful uptick on the unit side. Overall growth for the business came in around 20% because of some ASP true-ups from last year, but we were glad to see units gaining momentum. Revenue from Data and Services rose 64.4% versus a year ago, driven notably by our insights, or data licensing, segment, which posted 86.6% — a substantial step up from last year, from the prior quarter. We also posted adjusted EBITDA of negative $21.8 million, an improvement of $14.4 million compared with a year earlier and a considerable gain sequentially. So we remain firmly on track to better our EBITDA this quarter as we move toward cash flow and adjusted breakeven. Beyond that, the headline item for the quarter is that we announced the acquisition — or rather, signed an agreement to acquire — Ambry Genetics, a leader in hereditary screening whose business we've gotten to know well over the last few years; in fact, they serve as our biggest reference lab for the hereditary screening work we perform, and we invested considerable time with the team, learning the business, and we're simply thrilled to bring them into our world. The business is synergistic across all our offerings, from sequencing to eventually our Data business and our AI Applications business. They also speed up our journey to cash flow and adjusted EBITDA breakeven, since today the business is expanding at over 25%, which is impressive growth, but what's even better is that they produce substantial EBITDA. So they've pulled off something uncommon in our sector: a Genomics business with strong growth and a proprietary business model that is simultaneously profitable. And we're excited that, combined and on an annualized basis, the two of us will now also be adjusted EBITDA and cash flow positive; we're paying $600 million for the business, $375 million in cash and $225 million in equity, $125 million of which vests at closing, expected in early Q1, with the remaining $100 million locked up for a year. As for the multiples, we're paying about 1.9 times current revenue and roughly 15 times EBITDA; so we believe we're acquiring the business at an appealing price, and we're able to fund it largely through additional debt from Ares. And so the transaction is not materially dilutive at all to our equity, so overall, a fantastic quarter. With that said, we're happy to take any questions folks have.
Tejas Savant
analystHi everyone, good evening, and I appreciate you answering our questions. Eric, I'd like to begin with the Ambry announcement. To start, congratulations on it. Could you take us through why you decided to move into hereditary cancer testing? One thing people will surely ask about is whether that 25% growth figure you mentioned for the Ambry asset can hold up, given the inconsistent growth patterns some competitors have seen in that space. Then, secondly, could you speak to whether the organization is ready to keep advancing on the somatic portion of the portfolio, which includes your MRD effort, while simultaneously moving into these new verticals and bringing the transaction together? Or is the intention that you'll basically run it independently, since it was a well-run asset — you mentioned the EBITDA it produces — and more or less plan to think about folding it in at a later point?
Eric Lefkofsky
executiveYes. I'm glad to address that. To begin, Ambry aligns perfectly with the strategic platform we have today for Genomics, since we already provide hereditary testing now. We offer a test known as xG, which is among our primary product categories. It matters greatly to us, because our aim is to identify patients early, to be present for them during treatment, to be present as we monitor their disease as time goes on, and we hold to what has been at the core of our thesis, something we've discussed in the past: we think that — if you consider the parallel to Amazon and e-commerce — increasingly, physicians, care teams, and oncologists will prefer to partner with labs capable of helping them treat patients from start to finish, rather than dealing with five separate labs; they'll prefer a single lab, provided that lab can deliver comprehensive profiling. That's why we've long believed it matters to be involved in hereditary screening; it matters to be involved in somatic and liquid testing for therapy selection; it matters to be in MRD and monitoring. So this aligns perfectly with our strategic plans and what we're doing now. On top of that, the business has in fact been speeding up its growth rate. And when you examine the landscape, we think the hereditary market is fairly stable, with a growing number of insights proving relevant to understanding inherited cancer risk. So there is definitely growth in that area. Ambry specifically appears to be gaining share from competitors; we see nothing suggesting that will slow, and although the law of large numbers does tend to reduce growth rates — which holds for us and will hold for them — we expect it to be a significant grower for a while. Looking back over the last 12 months, nothing emerged from our close examination of the business that suggested any sort of systemic slowdown. So our expectation is that the business performs well and expands. It will generate greater profit, and it aligns perfectly with our footprint. Now turning to the opposite end of things—rather than identifying patients sooner, before cancer develops, at the moment it does—consider monitoring them after therapy for minimal disease detection, plus monitoring. As we've mentioned before, we essentially have two separate platforms in that area. The first is our tumor-naïve assay in colorectal cancer, where we run our own liquid assay, and the second is a tumor-informed product partnered with Personalis in lung, breast, and IO response. Our MRD portfolio, we believe, is broad. We consider it the correct portfolio for capturing share. Demand for our products has been very strong. Obviously reimbursement is the constraint, and unless both Personalis and we secure reimbursement, truly freeing those products is difficult. So my expectation is that this becomes a far more significant story in the years ahead, once reimbursement comes through and we genuinely begin ramping that portfolio.
Tejas Savant
analystUnderstood, that helps. Now perhaps shifting over to the data area — I believe you folks discussed the renewal of the Merck EMD contract. During the quarter, you also secured the expanded Takeda collaboration plus an additional one with BioNTech. Could you make clear if the TCV rose somewhat on a sequential basis? I realize you essentially restated that it was above $900 million once more, yet it would assist to simply give investors confidence that things are heading the right way; and then Jim, a question for you regarding the short-term dynamics at play. A question we frequently receive is that there's a $20 million, $25 million kind of quarter-over-quarter step-up baked into Street models for Q4 within the Data and Services business. So your visibility on that, considering the mixed commentary we've heard from CROs and other participants amid biopharma funding softness, would be useful.
Eric Lefkofsky
executiveLet me begin with the broader business, and then Jim can address the financial metric somewhat. The Data business keeps performing well. We were lucky that much of the strain others have been facing — we aren't shielded from it. Of course, there was in the past some extra tailwind when biotechs were going public and R&D budgets were bigger; thus we've definitely watched part of those tailwinds fade, yet the business overall stays truly robust; and actually, the growth rate for our data licensing business, at nearly 87%, isn't something we anticipate maintaining. Therefore we anticipate growth rates will decline. And so we have a lengthy — we possess solid cushion regarding constructing a durable, meaningful, fast-growing, large data business considering our position. And so on the whole, I'd say all things are heading the right way. One quick point on Merck: it's genuinely pleasing when a major client holding a sizable three-year data license reaches renewal time and you sign them again, deepening these relationships — I think that stands as proof the data delivers value. Our products deliver value. And what most folks fail to grasp when examining our Data businesses is that it isn't merely that we hold tons of data, which clearly we do. Rather, we've created an entire array of tools and data products enabling that data to be used by biotechs and pharmaceutical companies. That truly is the core differentiator. As for the overall metric of $900 million, I'll let Jim chime in.
Jim Rogers
executiveRight. So like we mentioned when Q2 wrapped up, that figure stood above $900 million, and it remains above $900 million once Q3 closed. Clearly, a substantial chunk of revenue got recognized during Q3 out of the amount sitting there at Q2. So once more, we keep replenishing that pool, and we believe a level above $900 million obviously provides us with really solid visibility looking ahead across the coming several years when it comes to data licensing. As for the bump up in Q4, from a data standpoint Q4 has always been our biggest quarter. Frequently we've got projects that sort of track pharma budget cycles, and therefore our own budgeting cycles. So having an increase in Q4 on the data licensing side isn't unusual for us.
Tejas Savant
analystUnderstood. That helps. Thanks for making room in your schedules, everyone.
Eric Lefkofsky
executiveThank you.
Rachel Vatnsdal
analystHello there, good afternoon. I appreciate you fielding these questions. To start with regarding the core Genomics segment, Eric, I think you said that this quarter saw an acceleration in unit growth. Could you therefore provide a breakdown of how volumes increased on a sequential basis? After that, might you go into even more detail on which specific test within that portfolio experienced quicker adoption?
Jim Rogers
executiveSure. In Q2, total volume came to roughly 66,500, while Q3 had approximately 69,000 tests. It's important to point out that neither figure includes any MRD testing. Thus, the quarter-over-quarter expansion we are observing stems from our core assays — xT, xR, xF, plus xG, which is expanding at a faster rate — though it remains a smaller base, meaning the bulk originates from xT, xR and xF.
Eric Lefkofsky
executiveAbsolutely, and as we hinted during the prior quarter, we anticipated some extra unit growth in this period, and it came through just as we thought—so that’s always good to witness.
Rachel Vatnsdal
analystGreat. Then for my follow-up question — during the prior quarter, you all brought up the topic of bringing on sales staff. My understanding is that about 60 new sales representatives came aboard during that period, and at first this simply resulted in reduced output while those folks were ramping up, along with certain territory realignments. So could you share an update on where sales force productivity stands right now? Also, how do you expect that to move as we ramp into 4Q and then into next year?
Eric Lefkofsky
executiveYes, I'll begin. What I'd say is the sales force is definitely becoming more productive each month as they receive training and get up to speed; historically, we've observed that bringing reps fully up to speed in our business can require six months to nine months. Our testing compendium is broad, so it does take some time. And our expectation is that they'll keep becoming more efficient. This doesn't carry the same weight for us as it might for other companies, given that we're now metering our investments. Consider the business roughly three quarters back — we were producing negative $40-plus million, versus negative $30-plus million in the prior quarter; at present it's just over $21 million of EBITDA; so on our own we're on a steady monthly trajectory toward reaching adjusted EBITDA positive within the next short period. That's before even counting the accelerant from Ambry, which clearly moves that up somewhat. Still, our sales force investments aren't so large that their productivity shortfall is creating any kind of financial turmoil — not in the least. It could simply mean that in a particular quarter, we might sell 1,000 fewer reps than anticipated, or 2,000. Consequently, the growth rate could shift from 23% to 25%, or from 22% to 24%; so when it comes to certain fluctuations versus our forecast, we can account for them by examining that productivity, yet it isn't truly significant, since this isn't a huge investment for us that we must push through in order to be financially healthy and on a solid path.
Eric Lefkofsky
executiveMichael Ryskin, Question: Thanks a lot for answering my question, and I appreciate the details you gave about Ambry before — congratulations on getting that deal done. The numbers behind it look quite strong, from what I can tell. I'd like to dig a bit deeper into the connection you already have with them, which you've mentioned before — that primary reference lab arrangement. What I'm trying to understand is this $300 million figure in revenue that they brought in — or that you're projecting for this year. How much of that would actually be new or additional, if you follow me? What I'm really asking is this: when you look at the business today, what share comes from their tie-up with you, and what share comes from somewhere else? And how are we supposed to frame the effect that this model will have in the coming year?
Eric Lefkofsky
executiveRight, so clearly the overwhelming majority doesn't overlap. That said, we haven't given precise figures on how it splits across our test. For the most part — look, the details wouldn't be all that interesting, so — the trouble is it would simply spark additional questions, since these sorts of things shift around somewhat. On top of that, our testing portfolio is fairly wide-ranging. We shouldn’t get into the pattern of covering each detail of each test on a quarterly basis. That being said, our hereditary screening, also called inherited cancer risk, was a more recent addition to what we offer. As Jim said moments ago, it remains fairly modest as a share of our broader Genomics segment, and most of Ambry’s operations are not finished.
Jim Rogers
executiveOne more thing worth mentioning is that our main point of contact is genetic counselors, while the test volume itself arrives by way of oncologists. That makes it quite complementary to our efforts.
Michael Ryskin
analystAll right, thank you. Moving on to the Genomics segment — 69,000 tests, and I believe you mentioned an ASP of 1,530, which shows decent sequential growth compared to 2Q and 1Q. Are there any specific trends worth highlighting when it comes to reimbursement? Did a specific payer join, or was it more of a general increase, and how should we view that line item moving forward? Should we expect this rate of improvement to persist?
Jim Rogers
executiveSure. On the reimbursement front, we've achieved some headway with commercial payers during the past couple of months; we added Blue Shield of Illinois, Blue Shield of California, and Avalon, essentially all in-network agreements that cover our entire therapy selection in inherited cancer panels, including xT, xR, xF, xG, and xT+. That resulted in modest quarter-over-quarter gains. I'd note there's no major step-up anticipated in Q4. Regarding ADLT status, the pricing review remains in progress. As a reminder, our goal is $4,500 per test for the xT CDx. We'll begin shifting volume to that from the assay in Q1 of 2025. That represents the next significant accelerant on the reimbursement side as we transition to that assay version.
Michael Ryskin
analystOkay, thank you very much.
Dan Brennan
analystThanks, I appreciate the questions. Perhaps regarding Ambry — since you two are partners, one would assume this wasn't a bidding situation. I just wanted to confirm that, or hear a bit about how the transaction came together. Also, is there anything you can share about the revenue growth rate you're assuming, or that we should model going forward? And does this deal bring any synergies?
Eric Lefkofsky
executiveSure, I'll take the first two. On whether it was competitive — Ambry did conduct a competitive process. They brought in banks, as I understand it, and evaluated their alternatives. You would need to look into it somewhat — since these are publicly traded firms, you can review certain remarks they've made in the past. However — I don't claim deep knowledge regarding Konica Minolta, yet I'm aware that at some stage, Ambry along with a separate operation had been combined. My understanding is that for a while, they intended to divest both together, before ultimately choosing to separate them. So there was a procedure involved, though it came with unexpected developments. We benefited from having solid familiarity with that operation. It was something we kept a close eye on. Our relationship with them was collaborative, which gave us the chance to observe how they performed across extended periods and become genuinely confident that this operation had staying power—that its financials were getting better—and that, provided we secured suitable conditions, buying it would create significant synergies for us, speeding up our company's progress regarding both the offerings we bring to customers and our path toward reaching positive EBITDA and cash flow, objectives we recognize as essential. Regarding growth on the top line, there are slides included in the investor deck that show what the combined business would look like. If the two were a single company right now, revenue would come to roughly $1 billion, and we offer a bit of insight there. Our models for 2025 aren't entirely finished, but we anticipate the merged operation expanding somewhere in the 23% to 25% range. Clearly, the combined entity would also be positive on both adjusted EBITDA and cash flow. So we find ourselves in a solid, healthy position — at scale, growing, and still pursuing our mission of bringing AI to diagnostics. Turning to synergies…
Jim Rogers
executiveWhen it comes to synergies, our plan is — since this is a well-run company, we intend for it to keep operating fairly independently in the near term, though there definitely are some synergies to capture. Take data, for instance: they lack a sizable data operation. Ours is large, and we can fold Ambry into it. On top of that, they operate mostly in-network — roughly 95% of their volume sits in networks — and their payer relationships are strong, which we hope to leverage on the Tempus side. So it's not as if immediate synergies are baked into our expectations. Down the road, we believe this is a very synergistic asset.
Dan Brennan
analystUnderstood. Thanks. As a quick follow-up, regarding what we might expect for the rest of the year — I believe either in the press release or perhaps during the prepared remarks, you mentioned that the genomics business should remain within that 25% to 30% range, and you reiterated the $700 million guidance for the year. So should we conclude that Genomics will be at 25% to 30% in 4Q, and then we can simply calculate what the remaining data business ought to grow at? Or are you considering something different on a segment basis for 4Q?
Eric Lefkofsky
executiveThat's likely something for Liz to address following this call, since I don't believe we have a buy segment, a quick snapshot of how I would break it down. But certainly, we do expect Genomics to fall within that 25% to 30% range, so you can sort of work backwards from there.
Jim Rogers
executiveCorrect, we don't expect anything major to change in Q4 regarding how these businesses have each been expanding on their own.
Eric Lefkofsky
executiveRight. That said, we did mention this, I believe, in the letter we sent — you shouldn’t count on the Data business expanding at a rate of 87%.
Jim Rogers
executiveCorrect.
Eric Lefkofsky
executiveWhat I'd say is that performance from this business has been really strong. That said, what matters much more to us is expansion over the long haul, somewhere around 25%, rather than quick boosts that, once we're up against them a year later, leave things swinging all over the place. Given the sheer size of the opportunity, and given where we sit in it — essentially among the top players delivering AI into health care and offering specific diagnostics — long-term growth is what we're after.
Dan Brennan
analystExcellent. Thanks very much.
Ryan MacDonald
analystHey there, congratulations on an outstanding quarter, and I appreciate you fielding my questions. Perhaps to begin, regarding the current situation for buying data — clearly there were some impressive, noteworthy agreements during the period. Could you discuss whether you are noticing any shifts in the way, say, more recent clients on the data side are making purchases or completing that very first transaction? Also, are you observing perhaps expansion or bigger initial commitments compared with, say, the prior 6 to 12 months, a stretch when buying data was somewhat more challenging? Thank you.
Eric Lefkofsky
executiveNo, I mean, I wouldn’t say — we are definitely experiencing ongoing robust demand for the data offerings we provide. This year has brought truly significant victories, plenty of positive momentum, and many major customers added to our roster. We’ve discussed a handful over the past several quarters, though certainly BioNTech stands out as an excellent fresh win for — achievements like that are wonderful new wins for us. Yet, as I noted, without a doubt the broader market lacks the same favorable winds it enjoyed several years back, when money moved around much more easily. Several years back, an abundance of biotechs had just IPO’d or secured funding and were eager to acquire data; these days, when you speak with biotechs, their focus is on conserving cash since conditions have simply changed. So the reality that we continue expanding and hold such a substantial backlog, I believe, speaks well to the worth our data offerings bring to the market; and my expectation is that as the environment evolves somewhat, we’ll capture some of those favorable winds possibly in 2025 or 2026, once capital starts moving more freely again. However, we have not observed any basic change in behaviors. Within our sector, customers typically start by purchasing a modest amount of data, then increase it, followed by an even larger transaction. After that, our aim is to bring them into some form of strategic partnership.
Ryan MacDonald
analystThat's really useful context. As a quick follow-up, I know this is only a modest piece of the business right now. But in the apps space, you recently put out word about a partnership with Northwestern Medicine, something around cardiology, and I believe they're using the ECG-AF algo. Could you expand a bit more on that partnership? And beyond that, is this beginning to lay out a path for how you see the app segment starting to establish its monetization approach down the road?
Eric Lefkofsky
executiveYes, you've got it exactly. I believe a growing number of big medical systems are working out ways to capitalize on this fresh wave of generative AI and large language model capabilities. They see these tools as accelerants for their capacity to care for patients and produce stronger outcomes. So they're working out how to incorporate that into their operations. And there are very few businesses at our scale, of our size, offering products in that space. So we feel lucky to hold quite deep ties with some of the finest medical centers globally, Northwestern being one of them; and all of us are working out the optimal approach to get these models into use. What's notable, and I think I've mentioned this for several quarters now, is my expectation that these models will be — to begin with, in our space, they already are in use at scale; but I expect that in the years ahead, they'll be in use at truly massive scale. And you'll see a huge number of individuals actually taking advantage of these algorithmic diagnostics. Having said that, it might not translate into much revenue, since you could have millions of individuals gaining some benefit from these things while not producing much revenue, because we still haven't worked out, at least here in the U.S., how to properly compensate for the value of these purely algorithmic diagnostics. So a key thing we devote a great deal of thought to is how we ultimately show Medicare and Medicaid and other commercial payers that these things deliver value, they cut costs, they boost outcomes, they extend longevity, and they ought to be reimbursed. And I believe the major turning point for the commercial side of our applications will arrive when reimbursement finally happens.
Andrew Brackmann
analystHello, and good afternoon. I appreciate you taking my questions. Perhaps to begin with Ambry — in the deck, you mentioned the health system relationships this could help advance for you. So at a broad level, could you discuss how this acquisition might speed up or expand some of those partnerships? Essentially, in what ways does this make it easier for you to become the provider those groups turn to first? Thank you.
Jim Rogers
executiveSure. Regarding the payer relationships Ambry holds, they are clearly mainly an in-network lab, while we are mainly an out-of-network lab. In certain of those conversations, they bring considerable experience working with commercial payers. Then when it comes to health systems, as I said earlier, their main point of contact is genetic counselors, whereas we mostly engage with oncologists. So once more, by strengthening those ties throughout the whole ecosystem on the provider side, we think we will bolster our standing with hospitals.
Eric Lefkofsky
executiveYeah. Take a solid illustration: this morning I visited 2 quite big academic medical centers, an NCI Cancer Center, and each had something like precision medicine units plus their cancer center, so you had a cancer center. In both places, the same teams handle hereditary screening for cancer patients, therapy selection, genomic profiling for those patients, and clearly now MRD along with monitoring. So they don't split things across separate teams, correct? It's like, "Oh, if you need hereditary screening done, that's handled over there" — no, it's one set of people attempting to determine how to deliver precision medicines to their cancer patients, the ones considering Ambry and considering Tempus. That makes us, in my view, extremely synergistic on that front. And essentially everyone we speak with wants vendors capable of supporting them more comprehensively. The prevailing direction is: can I deal with fewer parties who can assist me end-to-end in a more integrated, comprehensive way, rather than relying on tons and tons and tons of tiny sequencing providers? So our sense is this only bolsters our platform as a whole.
Andrew Brackmann
analystGreat. Then I'd like to revisit something you said in response to an earlier question about profitability. So in terms of juggling investments against this push toward profitability, how are we supposed to think about that going forward? Does this acquisition alter that approach at all? Or should we still expect the same forward momentum? Thanks.
Eric Lefkofsky
executiveSo when we became a public company, only 5 months back, we told people we had a disciplined route toward getting to EBITDA positive — that we weren't — that our aim was essentially to take the gross profit dollar growth we were producing and create some leverage, so our losses would shrink rather than what a few others in our sector have done, which is either more or less keep loss levels high or actually move in the opposite direction and put more money in. Given that we're turning 10 next year, we believed that was wise, and we simply thought that with our size and scale, being sustainable and not burning money mattered as a milestone. How we want to harvest profits hasn't been decided yet; so what I can say with confidence is that, particularly because of this acquisition, that hurdle is behind us; that box has been checked, so to speak. On an annualized basis, we're now a business that's EBITDA positive, cash flow positive, and sustainable, but we need to give some thought to how we want to harvest the EBITDA we're going to generate versus invest in the future, and I wouldn't — I don't — I think our focus over the next several years is more on making sure we can sustain our growth rate, not trying to generate an extra $50 million of EBITDA in a given year. So I think you'll, I think, see us make those trade-offs, but we remain disciplined and we want to run a good business; and so I think hopefully we'll find the right balance.
Analyst
analystHello, and thank you for taking my question; John here, filling in for Dave. To begin with, I just wanted to ask — lately there have been some problems involving Myriad Genetics and United when it comes to securing reimbursement for GeneSight. Any perspective from you on how reimbursement might develop across psychiatric conditions and pharmacogenomics for the industry going forward?
Jim Rogers
executiveYes, on that one I have plenty to say. Our neuropsych business is fairly small, so any disruption to reimbursement in that area carries a very significant effect on our overall growth rate. Regarding how things ultimately shake out over the longer term, clearly this news emerged last week. So how other payers will respond to it and so forth is still unknown, but the impact on our business is very minimal.
Analyst
analystUnderstood. Thanks. And second, there has been quite a bit of discussion regarding reimbursement for transcriptomics as well as genomics; therefore I'd like to pose this in a somewhat different manner. Could you explain how your CGP test delivers distinct value compared with rivals? And does your billing misalign with the value you believe it offers?
Eric Lefkofsky
executiveWell, alright, to start with, no, regarding our billing — we don't believe it misaligns. The billing rates aren't something we determine. Those rates get determined by — for Medicare — Medicaid through CMS and through our local MAX during their process. Thus we have — we make use of billing rates in both MolDx and NGS. In fact, we belong to two MAXs. Consequently our blended rate of $1,530 across all our tests includes certain tests reimbursed at x amount plus certain tests reimbursed at y amount. And ultimately, we adhere to AMA codes, we adhere to the reimbursement pathways established by our MAX, and then we adhere to whatever payers are paying in their local areas. Thus, for instance, Jim noted that we recently contracted with Blue Cross and Blue Shield in Illinois and in California, and those entities pay a somewhat discounted rate compared to Medicare for both our DNA test. Likewise for our RNA test and likewise for our liquid test. So at this point, I mean, on many, many, many occasions, many, many, many, many separate occasions. Independent MAX and commercial payers have examined our DNA tests, our RNA tests, our liquid test and set rates, and those figures have all somewhat converged at the same point. Therefore we don't anticipate anything shifting there. We consider that fairly well settled; we do anticipate that our rates for our DNA test will rise somewhat given our ADLT status, we don't know what the amount will be and we have long adopted the stance of not pledging to or projecting ASP gains before they materialize. So if you examine this year, we essentially said, hey, we're near $1,400, and that's what's visible to us and currently we're at $1,530. But we don't claim we're at $1,530, and then we can see $1,700. We simply look at it and say, "Hey, we're lucky to have a high margin and a profitable business at this point. And should there be ASP lift, that's wonderful. But it isn't under our control and it must all be independently verified. And so I believe repeatedly, it has been.
Analyst
analystGot it. Thank you.
Operator
operatorThat brings us to the end of the Q&A portion. So we're going to wrap up today's conference call here. Thanks to everyone for joining us. You can go ahead and disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.